Network Pharmacology, Molecular Docking, Hematological Evaluation, and in vivo Evidence Support Sakuranetin as a Redox and Inflammation-Modulating Agent against Skin Tumorigenesis
Skin Pharmacology and Physiology · 10.04.2026 · 1-14
DOI: 10.1159/000551641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Skin Pharmacology and Physiology, online erschienen am 10.04.2026. Verfasst von Humood Al Shmrany und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia, h.alshmrany@psa…. Hauptthemen laut MEDLINE: Skin Neoplasms, Flavonoids, Anti-Inflammatory Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction
Skin cancer is a growing global health concern, often linked to environmental carcinogens like ultraviolet radiation and chemicals. This study investigated the protective effects of sakuranetin against DMBA-induced skin cancer in mice.
Methods
A total of 24 mice were randomly divided into four groups: a control group, a disease control group, and two treatment groups that received sakuranetin orally at 10 mg/kg and 20 mg/kg post-DMBA exposure for 8 weeks. Tumorigenesis was evaluated through histopathology, followed by hematological (HB, RBCs, MCV, WBCs, PCV, and MCH), antioxidant enzyme levels (SOD, CAT, GSH), lipid peroxidation, pro-inflammatory markers (IL-1β, IL-6, TNF-α, COX-2), NF-κB, and caspase-3. Additionally, network pharmacology and molecular docking were performed.
Results
Treatment with sakuranetin restored the abnormal hematological parameters, restored antioxidant enzyme levels (SOD, CAT, GSH), reduced lipid peroxidation, and significantly reduced pro-inflammatory markers, NF-κB, while increased caspase-3. Histological examination confirmed reduced neoplastic changes. Sakuranetin at the dose of 20 mg/kg completely prevents tumor development. Network pharmacology identified 53 potential sakuranetin targets, and molecular docking revealed strong binding affinities with key proteins, including COX-2 (−9.2), TGF-β (−8.5), NF-κB (−8.1), caspase-3 (−6.8), and VEGF (−5.9), which are involved in cancer pathways.
Conclusion
Sakuranetin effectively mitigated DMBA-induced skin cancer through antioxidant, anti-inflammatory, and pro-apoptotic mechanisms. These findings suggest its potential as a multi-targeted therapeutic candidate for skin cancer prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia, h.alshmrany@psau.edu.sa.
- Department of Medical Laboratory, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia.
Zitieren
APA
Al Shmrany, H., & Binshaya, A. S. (2026). Network Pharmacology, Molecular Docking, Hematological Evaluation, and in vivo Evidence Support Sakuranetin as a Redox and Inflammation-Modulating Agent against Skin Tumorigenesis. Skin Pharmacology and Physiology, 1-14. https://doi.org/10.1159/000551641
Vancouver
Al Shmrany H, Binshaya AS. Network Pharmacology, Molecular Docking, Hematological Evaluation, and in vivo Evidence Support Sakuranetin as a Redox and Inflammation-Modulating Agent against Skin Tumorigenesis. Skin Pharmacology and Physiology. 2026:1-14. doi:10.1159/000551641
BibTeX
@article{AlShmrany2026,
author = {Al Shmrany, Humood and Binshaya, Abdulkarim S},
title = {Network Pharmacology, Molecular Docking, Hematological Evaluation, and in vivo Evidence Support Sakuranetin as a Redox and Inflammation-Modulating Agent against Skin Tumorigenesis},
journal = {Skin Pharmacology and Physiology},
year = {2026},
pages = {1--14},
doi = {10.1159/000551641}
}
EUVIMED